D-1236-2020 Class II Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-1236-2020 was initiated by Aurobindo Pharma USA Inc. on March 18, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed The recall status is terminated (terminated March 25, 2024). Affected quantity: 2101 units.

Recall Details

Product Type
Drugs
Report Date
April 22, 2020
Initiation Date
March 18, 2020
Termination Date
March 25, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2101 units

Product Description

Phentermine Hydrochloride Capsules, USP 15mg, 100-count bottles, Distributed by: Aurobindo Phama USA, Inc. Dayton, NJ 08810, NDC 13107-105-01

Reason for Recall

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Distribution Pattern

Nationwide within the United States

Code Information

Lot #: 105180004A, Exp. Date 03/2020